Guner Kilic1 , Gulce Ecem Kilic2, Nuket Bayram Kayar3, Ozan Durmaz4, Adnan Ozkahraman4, Sevki Konur5, Ramazan Dertli6, Yusuf Kayar7
1Etlik City Hospital, Department of Gastroenterology, Halil Sezai Erkut Street, Yenimahalle/Ankara 06170,; 2Ankara Training and Research Hospital, Department of Endocrine and Metabolic Diseases, Hacettepe, Ulucanlar Cd. No:89, 06230 Alt?nda?/Ankara,; 3Ipekyolu Merkez No. 3 Family Health Center, Department of Family Medicine, Halilaga, Saglik Sk., 65140 Ipekyolu/Van,; 4Van Training and Research Hospital, Department of Internal Medicine, Suphan Mahallesi Hava Yolu Junction, 1st Kilometer Edremit/Van,; 5Duzce University Faculty of Medicine, Department of Gastroenterology, Yörük, Düzce Univ., 81620 Yörük/Duzce Merkez/Duzce,; 6Necmettin Erbakan University, Department of Gastroenterology, Yunus Emre, Akyoku? Sk., 42080 Meram/Konya,; 7Van Training and Research Hospital, Department of Gastroenterology, Suphan Mahallesi Hava Yolu Junction 1st Kilometer Edremit/Van, Turkey.For correspondence:- Guner Kilic Email: gunerrkilic@gmail.com Tel:+905323168421
Received: 2 August 2024 Accepted: 6 December 2024 Published: 30 December 2024
Citation: Kilic G, Kilic GE, Kayar NB, Durmaz O, Ozkahraman A, Konur S, et al. Evaluating the combination of amoxicillin, gemifloxacin and rabeprazole therapy for Helicobacter pylori eradication in young and older adult patients. Trop J Pharm Res 2024; 23(12):2073-2078 doi: 10.4314/tjpr.v23i12.12
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To assess the effectiveness, safety and adverse effects of treatment regimen combining amoxicillin, gemifloxacin and rabeprazole for eradicating Helicobacter pylori in adult population. Methods: A total of 211 patients comprising 33 patients (15.6 %) from the older adult group and 178 patients (84.4 %) from the younger adult group who visited Van Training and Research Hospital, Turkey were included in this study. Treatment, made up of amoxicillin (1000 mg) and rabeprazole (20 mg), was administered 12 hourly and gemifloxacin (320 mg) once daily to all patients for 7 days. Thereafter, patients were evaluated for H. pylori eradication by examining antigens in feces (immunochromatographically based, qualitatively), drug compliance and treatment tolerance. Results: Post-treatment investigations showed that H. pylori was completely eradicated in 187 patients (88.6 %), while eradication was not achieved in 24 patients (11.4 %). In the older adult group, H. pylori was successfully eradicated in 27 of 33 patients (81.8 %). Excluding a total of 9 patients who did not complete treatment due to side effects, H. pylori eradication was achieved in 184 of 202 patients (91 %). Conclusion: This combination of three antibiotics exhibits a high rate of eradication of H. pylori among adult patients, even when administered for a short period (one week). This investigation should be carried out using a larger and more diverse patient population to validate the outcomes reported in this study
Archives
News Updates